TWI874925B - 癌症治療 - Google Patents

癌症治療 Download PDF

Info

Publication number
TWI874925B
TWI874925B TW112109467A TW112109467A TWI874925B TW I874925 B TWI874925 B TW I874925B TW 112109467 A TW112109467 A TW 112109467A TW 112109467 A TW112109467 A TW 112109467A TW I874925 B TWI874925 B TW I874925B
Authority
TW
Taiwan
Prior art keywords
erdafitinib
treatment
serum phosphate
cancer
specifically
Prior art date
Application number
TW112109467A
Other languages
English (en)
Chinese (zh)
Other versions
TW202402290A (zh
Inventor
金姆 史戴肯斯
璜斯 佩雷斯路斯歐
彼得 迪波雷
安潔莉 阿凡德哈尼
尤哈恩 羅莉特
瑞迪卡 艾蓮恩 西克爾
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI874925(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202402290A publication Critical patent/TW202402290A/zh
Application granted granted Critical
Publication of TWI874925B publication Critical patent/TWI874925B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
TW112109467A 2017-02-06 2018-02-02 癌症治療 TWI874925B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
US62/455,211 2017-02-06
EP17209098 2017-12-20
EP17209098.7 2017-12-20

Publications (2)

Publication Number Publication Date
TW202402290A TW202402290A (zh) 2024-01-16
TWI874925B true TWI874925B (zh) 2025-03-01

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112109467A TWI874925B (zh) 2017-02-06 2018-02-02 癌症治療

Country Status (25)

Country Link
US (2) US11077106B2 (enExample)
EP (2) EP3576740B1 (enExample)
JP (3) JP2020505425A (enExample)
KR (2) KR20250069693A (enExample)
CN (1) CN110198716A (enExample)
AU (2) AU2018216969B2 (enExample)
BR (1) BR112019016043A2 (enExample)
CA (1) CA3049737A1 (enExample)
DK (1) DK3576740T3 (enExample)
ES (1) ES2953005T3 (enExample)
FI (1) FI3576740T3 (enExample)
HR (1) HRP20230697T1 (enExample)
HU (1) HUE062453T2 (enExample)
IL (1) IL268463A (enExample)
JO (1) JOP20190190A1 (enExample)
LT (1) LT3576740T (enExample)
MX (2) MX2019009304A (enExample)
PH (1) PH12019501885A1 (enExample)
PL (1) PL3576740T3 (enExample)
RS (1) RS64778B1 (enExample)
SG (2) SG10202105110VA (enExample)
SI (1) SI3576740T1 (enExample)
SM (1) SMT202300233T1 (enExample)
TW (1) TWI874925B (enExample)
UA (1) UA126336C2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957146A (zh) 2014-09-26 2022-01-21 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
SG11202109902SA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202109854RA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JOP20220182A1 (ar) * 2020-02-12 2023-01-30 Janssen Pharmaceutica Nv مثبطات كيناز تيروسين fgfr لعلاج سرطان المثانة الغازي غير العضلي عالي الخطورة
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
WO2024241297A1 (en) * 2023-05-24 2024-11-28 Janssen Pharmaceutica Nv Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) * 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 , C HIERRO, et al., "Fibroblast growth factor (FGF) receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors", Seminars in Oncology, 42(6), Elsevier, 2015: 801~819. *
期刊 , J TABERNERO, et al., "Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors", Journal of Clinical Oncology, 33(30), ASCO, 2015: 3401~3408.; *

Also Published As

Publication number Publication date
UA126336C2 (uk) 2022-09-21
JP7668777B2 (ja) 2025-04-25
SG11201907199QA (en) 2019-09-27
IL268463A (en) 2019-09-26
SG10202105110VA (en) 2021-06-29
SMT202300233T1 (it) 2023-09-06
LT3576740T (lt) 2023-08-10
PH12019501885A1 (en) 2020-06-29
TW202402290A (zh) 2024-01-16
AU2024201871A1 (en) 2024-04-11
MX2019009304A (es) 2019-09-19
PL3576740T3 (pl) 2023-09-11
AU2018216969B2 (en) 2024-04-11
AU2018216969A1 (en) 2019-07-25
DK3576740T3 (da) 2023-07-24
BR112019016043A2 (pt) 2020-03-31
EP4286005A3 (en) 2024-03-06
JP2020505425A (ja) 2020-02-20
CN110198716A (zh) 2019-09-03
JP2025024064A (ja) 2025-02-19
KR20250069693A (ko) 2025-05-19
JOP20190190A1 (ar) 2019-08-04
CA3049737A1 (en) 2018-08-09
SI3576740T1 (sl) 2023-10-30
US20220110935A1 (en) 2022-04-14
JP2023022190A (ja) 2023-02-14
MX2022007955A (es) 2022-07-27
HUE062453T2 (hu) 2023-11-28
US11077106B2 (en) 2021-08-03
RS64778B1 (sr) 2023-11-30
FI3576740T3 (fi) 2023-08-31
EP3576740B1 (en) 2023-06-14
KR20190110581A (ko) 2019-09-30
EP4286005A2 (en) 2023-12-06
HRP20230697T1 (hr) 2023-10-13
EP3576740A1 (en) 2019-12-11
ES2953005T3 (es) 2023-11-07
US20200022976A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
TWI874925B (zh) 癌症治療
TWI798199B (zh) 癌症治療
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
CN113645975A (zh) 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
TWI863962B (zh) 癌症治療
US20220054484A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40103983A (en) Cancer treatment
HK40013982A (en) Cancer treatment
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment
WO2022171064A1 (zh) 烟酰胺及含有其的组合物的制药用途
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma